Rheumatology (Oxford). 2016 Oct;55(10):1714-25. Epub 2016 Jan 20. DOI: 10.1093/rheumatology/kev410 PMID: 26790456 [PubMed – in process]
Traditional BTMs have been used for years to help with fracture risk prediction and in particular for treatment monitoring. Clinical use of the new biochemical markers has not been established so far. Their relationship with fracture risk is still under investigation, and their use as treatment monitoring tools needs to be studied. In fact, their role is probably dependent on a new approach based on our understanding of bone physiology. These new markers will be helpful for exploring the physiological and pathological relations between the bone and other organs, and to monitor joint diseases, chronic kidney disease – mineral and bone disorder (CKD-MBD) and cardiovascular disease. mechanisms in the bone or other organs.
Autor: Chapurlat RD, Confavreux CB
